Home 2018-03-06T14:32:48+00:00

Liver Testing Through a New Investigative Tool

liver health image

Function Matters

HepQuant: A minimally invasive assessment of chronic liver disease

HepQuant Test to Measure Liver

New Investigative Tools to Evaluate the Liver

HepQuant Research Center and Lab

assessment of chronic liver disease

Novel technology for minimally invasive

Liver Function Tests: Breaking Through Conventional Thinking About Liver Health Testing

HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.

Upcoming Events

Dr. Greg Everson Will Be Presenting at NASH Summit

Dr. Greg Everson, inventor of the HepQuant tests and founder of HepQuant, LLC, will be presenting at the NASH Summit in Boston, on Tuesday, April 24th at 12 p.m.

Come listen to Dr. Everson speak about “The HepQuant Function Tests for Assessing Liver Disease.” His presentation will be part of the Clinical Stream track.

EASL 2018 HepQuant senior executives will be attending European Association for the Study of the Liver (EASL) International Liver Congress™ in Paris, April 11-15, 2018.

HepQuant will attend The Emerging Trends Conference – Cholangiopathies: The Dawn of Curative Treatments? conference March 16-17, 2018 in Arlington, VA.

We will also be attending the AASLD Drug Induced Liver Injury Annual Conference in June.

liver function test image

Recently Presented

HepQuant was discussed by at the October 2017 AASLD Meeting during an NAFLD Debrief.  For AASLD member access to the presentation, please click here.

Here is a link to our 2017 AASLD presentation on “Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test.”

A recent presentation at the American Society of Clinical Oncology (ASCO) meeting highlighted a new potential use of HepQuant SHUNT – monitoring impact of cancer treatment on global liver function.  (Link to abstract and poster)


These links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.